SecBot SecBot
8-K ·Filed Aug 6, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001104659-26-091619
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q2 beat and potential guidance raise signal accelerating commercial adoption of Amtagvi. Traders should watch for the formal guidance update in Q3 and upcoming ESMO data presentations (Oct 23-27) for lifileucel in sarcomas and frontline melanoma, which could be additional catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

IOVA drug pipeline →

Amtagvi

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Next catalyst
BLA filing · 2027

What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.21
T+0 close · Aug 6, 2026 · via day close
Latest settled
+36.55%
T+60 · $8.48
Vs SPY
+38.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $6.21entry
  2. T+1 · 3mo ago +2.09%α +1.48% · $6.34
  3. T+5 · 3mo ago +4.99%α +3.78% · $6.52
  4. T+20 · 3mo ago +40.10%α +39.50% · $8.70
  5. T+60 · 18d ago +36.55%α +38.22% · $8.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi revenue of ~$91M. Gross margin improved to 56%, and the net loss narrowed to -$0.11/share from -$0.33/share YoY. The company is reviewing its FY26 revenue guidance of $350M-$370M for a potential raise, while advancing its pipeline with FDA Fast Track Designation for lifileucel in soft tissue sarcomas.

Key Financial Metrics

EPS
−$0.11
est −$0.13 · +15.4%
Revenue
$99.3M
est $87.8M · +13.1% · +66.0% YoY
Rating
strong beat
Guidance
$350M-$370M
maintained
Gross Margin
56%

Key Facts

  • Total product revenue of ~$99.3M, up 66% YoY from ~$59.95M in Q2 2025.
  • U.S. Amtagvi revenue reached ~$91M, up 40% from Q4 2025.
  • Gross margin improved to 56% from 41% in Q1 2026.
  • Net loss per share narrowed to -$0.11 from -$0.33 YoY, beating consensus of -$0.13.
  • Company reviewing FY26 revenue guidance of $350M-$370M for a potential raise.
  • FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS and DDLPS).
  • Cash position of ~$304M expected to fund operations into 2H28.

Financial Impact

Record quarterly revenue of $99.3M, 66% YoY growth; net loss narrowed by $64.3M YoY to $47.3M.

revenueepsgross margincash position

Risk Factors

  • Revenue growth dependent on continued Amtagvi adoption and ATC network expansion.
  • Company remains unprofitable with operating losses; path to profitability uncertain.
  • Clinical pipeline risks: trial enrollment, regulatory approvals, and competition.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-091619
Document: tm2622322d1_8k.htm0001104659-26-091619
Document: 0001104659-26-091619-index-headers.html0001104659-26-091619
Document: 0001104659-26-091619-index.html0001104659-26-091619
Document: 0001104659-26-091619.txt0001104659-26-091619
8-K Data (Synthetic)0001104659-26-091619

Track record

21 reports on IOVA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026